Could China’s New Ozempic-like Drugs Beat Out Current Weight-Loss Medications?
SMRTR summary
Chinese pharmaceutical companies are developing innovative obesity drugs, including ecnoglutide, which outperformed placebo in clinical trials. Participants lost up to 13.8 kg over 48 weeks, with 92.8% losing at least 5% of body weight at the maximum dose. These new GLP-1 drugs target multiple pathways and aim to treat obesity-related complications like heart disease and diabetes.
SMRTR provides this summary for quick context. The original article belongs to Scientific American.
Read the original article